Antimalarial medication

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

Retrieved on: 
Friday, January 5, 2024
Doctor of Pharmacy, Partnership, Infection, NIAID, Antimalarial medication, Hope, SAN, Doctor of Philosophy, COVID-19, Series, Growth, Patient, Management

"We are pleased and honored to have our new directors join the Revagenix board.

Key Points: 
  • "We are pleased and honored to have our new directors join the Revagenix board.
  • These additions will bolster and complement our leadership team's extensive experience in anti-infectives to address the scientific and commercial challenges in the field."
  • The Series B financing complements ongoing funding from two product development contracts with the National Institute of Allergy and Infectious Diseases (NIAID).
  • As part of this transition, two former directors, Andrew Calabrese and Aleks Engel will step down from the board.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Retrieved on: 
Friday, January 5, 2024
Mucorales, Conference, Aspergillosis, Survival, Task, Infection, Biotechnology, NIAID, A65, Lower respiratory tract infection, Antimalarial medication, Trial of the century, Bangladesh Technical Education Board, AAAM, NIH, Vaccine

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis

Key Points: 
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis
    In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice.
  • Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy.
  • “The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp candidate SCY-247,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS.
  • “Groundbreaking treatment options are urgently needed to address the significant limitations in effective therapies for devastating and very often lethal fungal diseases such as mucormycosis.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
NDA, Security (finance), IND, Investment, Risk, GSK plc, Tablet, Biotechnology, Hansoh Pharmaceutical, Mucorales, VVC, Research, Data analysis, Medical Mycology, Antimalarial medication, FDA, FURI, GSK, Candidiasis, NIH, TIMM, Phase, Congress, Candida auris, Cryptocurrency, Pharmaceutical industry, Beauty salon

Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.

Key Points: 
  • Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.
  • SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp.
  • Cash, cash equivalents and investments totaled $105.2 million on September 30, 2023, compared to $73.5 million on December 31, 2022.
  • Based upon the company’s current operating plan, SCYNEXIS believes that its existing cash, cash equivalents and investments provides a cash runway beyond two years.

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
Monday, November 20, 2023
Select, CDI, Safety, Entrepreneurship, Fungal infection, WHO, AVP, Risk, Government, RN, WAAW, Sepsis, Patient, Infection, Antimalarial medication, Death, Drug resistance, Health, AMR, Invention, Acute kidney injury, Cancer, Diagnosis, Blood culture, Antimicrobial resistance, Hospital, Clostridioides difficile infection, Public, Education, Bloodstream infections, Pharmaceutical industry, Nursing

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Retrieved on: 
Tuesday, October 31, 2023
KOSDAQ, Trial of the century, South Korea, MSSA, Bacteriophage, Biofilm, Intron, Gram-positive bacteria, Infection, Virus, Exercise, Biotechnology, A-DNA, Antimalarial medication, MRSA, LR, Bacteria, Korea, Patient, Death, Pharmaceutical industry, Vaccine, Basel, Allschwil

Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.

Key Points: 
  • Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.
  • Over the course of 2024, Basilea will investigate various hypotheses in a number of preclinical studies to determine the optimal future clinical development program for tonabacase.
  • Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license tonabacase for further clinical development and commercialization.
  • This transaction has no impact on Basilea’s financial guidance for 2023, provided on August 15, 2023.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023
Yeast, TIMM, European Confederation, IV, Antimalarial medication, Auris, Candida albicans, Biotechnology, Congress, Professor, ECMM, Mouse, Candida auris, University of Graz, University, Medical Mycology, Fungal infection, Patient, Associate, Mycology, Pharmaceutical industry

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

Retrieved on: 
Monday, October 16, 2023
Congress, Medical Mycology, Antimalarial medication, TIMM, EEST, Biotechnology, EDT, Pharmaceutical industry, Aspergillus

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.

Key Points: 
  • JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.
  • Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
    Time: 3:35 p.m EEST / 8:35 a.m. EDT

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

SCYNEXIS to Participate in September Investor Conferences

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Antimalarial medication, Pharmaceutical industry

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

Key Points: 
  • JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Retrieved on: 
Wednesday, August 23, 2023
Regulation of therapeutic goods, Infection, Antimalarial medication, Clinical trial, Foot, ASX, FSE, COVID, Burn, 2018 Vuelta a España, Stage 1 to Stage 11, Erythema, Patient, Swelling, Observation, Genetically modified bacteria, Burns, TGA, Safety, RCE, Pharmaceutical industry

“We thank the West Australian Government for sponsoring this investigator-led topical burn wound infection trial,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “We thank the West Australian Government for sponsoring this investigator-led topical burn wound infection trial,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “The patient data received has paved the way to advance this new class of anti-infective as a topical application against deadly bacterial pathogens and a broad range of infectious diseases.
  • Endpoints of the trial include clinical wound assessment, graded for specific parameters such as erythema, hyper granulation, swelling, and discharge, and microbial cultures of wound swabs.
  • Stage 2 of the clinical trial is expected to be a randomized ‘head-to-head’ study in patients with infected burn wounds, where R327G will be compared to the current standard of care.